Xcovery Holdings has announced an agreement with EVERSANA, a leading provider of commercialisation services to the global life sciences industry, to support and expand the US commercial launch of ENSACOVE (ensartinib), the company's novel therapy for adult patients with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Under the agreement, EVERSANA will provide comprehensive end?to?end commercialisation services for Xcovery, including but not limited to agency of record, market access, commercial and medical teams to support the company's strategy to make Ensacove available to more patients across the US.

"The approval of Ensartinib was a major milestone in our mission to advance precision oncology. As we expand the US launch of ENSACOVE, we are focused on ensuring that patients and providers have the support they need. EVERSANA brings highly experienced, scalable commercialisation capabilities, and we're pleased to partner with them to broaden patient access," said Giovanni Selvaggi, MD, Chief Medical Officer, Xcovery Holdings, Inc.

Ensacove (ensartinib) is a next generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals. It is indicated for the treatment of adult patients with ALK-positive locally advanced or metastatic NSCLC as detected by an FDA-approved test who have not previously received an ALK inhibitor and is now available in the US as a treatment for these patients.

"EVERSANA was built to help companies just like Xcovery implement more impactful commercial strategies which will allow more patients to benefit from therapies like Ensartinib," said Gregory Skalicky, President, EVERSANA.